Physician profile
Cathi Stephens
NPI 1295158111
$3,243.38
in general payments reported to CMS, 2019-2025
19 companies · $891 in 2025
The $891 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $462 · 2023: $1,143 · 2024: $748 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.43 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.77 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $292.69 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $274.93 | 2022-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $261.98 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $216.52 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $214.01 | 2023-2025 | Spravato |
| Neurocrine Biosciences, INC. | $176.72 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $163.43 | 2022-2025 | Fanapt, Hetlioz |
| Indivior INC. | $162.79 | 2024-2025 | Sublocade |
| Neuronetics, INC. | $159.32 | 2022-2023 | Neurostar Tms Therapy System |
| Lundbeck LLC | $103.76 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $88.01 | 2022-2023 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $76.04 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $53.73 | 2023-2024 | Qelbree, Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $52.88 | 2023 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $51.74 | 2024-2025 | Cobenfy |
| Corium, LLC | $50.22 | 2025 | Azstarys |
| Sage Therapeutics, LLC | $28.41 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathi Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.